These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 15535403)
1. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy. Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403 [TBL] [Abstract][Full Text] [Related]
2. Strategies for management and treatment of dyslipidemia in HIV/AIDS. Sax PE AIDS Care; 2006 Feb; 18(2):149-57. PubMed ID: 16338773 [TBL] [Abstract][Full Text] [Related]
3. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625 [TBL] [Abstract][Full Text] [Related]
4. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Calza L; Manfredi R; Chiodo F J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323 [TBL] [Abstract][Full Text] [Related]
5. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F; HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977 [TBL] [Abstract][Full Text] [Related]
6. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. Manfredi R; Chiodo F J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549 [TBL] [Abstract][Full Text] [Related]
7. HIV protease inhibitors and dyslipidemia. Clotet B; Negredo E AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104 [TBL] [Abstract][Full Text] [Related]
8. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055 [TBL] [Abstract][Full Text] [Related]
9. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752 [TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880 [TBL] [Abstract][Full Text] [Related]
11. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079 [TBL] [Abstract][Full Text] [Related]
12. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors. Hiransuthikul N; Hiransuthikul P; Kanasook Y Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249 [TBL] [Abstract][Full Text] [Related]
13. Interpreting clinical trials of diabetic dyslipidaemia: new insights. Wierzbicki AS Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560 [TBL] [Abstract][Full Text] [Related]
14. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
16. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
18. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821 [TBL] [Abstract][Full Text] [Related]
19. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504 [TBL] [Abstract][Full Text] [Related]
20. HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies. Nolan DP; O'Connor MB; O'Connor C; Moriarty M; O'Leary A; Bergin C Int J STD AIDS; 2010 Jan; 21(1):75-6. PubMed ID: 19884356 [No Abstract] [Full Text] [Related] [Next] [New Search]